Cellular Intelligence is building a universal foundation model for cell signaling to predict and control how cells behave. The company is clinical-stage, with a Phase 2-ready, FDA Fast Track program for Parkinson's acquired from Novo Nordisk in 2026. Founded by Chorus.ai founder Dr. Micha Breakstone with faculty from MIT, Harvard Medical School, Penn, and UW, Cellular Intelligence is based in Boston and backed by $75M+ from Khosla Ventures, CZI, Novo Nordisk, and AMD Ventures.